TACROLIMUS
Venous Thromboembolism
Thomas Jefferson UniversitySmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Venous Thromboembolism cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
WARFARIN Northern Jiangsu People's Hospital | Phase 4 | A |
Apixaban Regeneron Pharmaceuticals | Phase 4 | BBB |
Apixaban Northern Jiangsu People's Hospital | Phase 4 | BBB |
Acetylsalicylic Acid Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 | BBB |
NADROPARIN Rijnstate Hospital | Phase 4 | BBB |
View all 35 →
Same molecule, other indications
TACROLIMUS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →